X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
canakinumab (497) 497
index medicus (262) 262
anakinra (215) 215
humans (193) 193
rheumatology (150) 150
inflammation (112) 112
interleukin-1 (91) 91
male (79) 79
arthritis (78) 78
female (78) 78
efficacy (72) 72
antibodies, monoclonal - therapeutic use (70) 70
familial mediterranean fever (65) 65
rilonacept (64) 64
double-blind (63) 63
cytokines (62) 62
treatment outcome (62) 62
colchicine (58) 58
juvenile idiopathic arthritis (58) 58
gout (54) 54
interleukins (53) 53
pharmacology & pharmacy (52) 52
adult (51) 51
atherosclerosis (51) 51
rheumatoid-arthritis (51) 51
children (48) 48
medicine & public health (48) 48
interleukin-1 receptor antagonist (45) 45
interleukin 1 receptor antagonist protein - therapeutic use (44) 44
interleukin-1beta - antagonists & inhibitors (44) 44
child (43) 43
c-reactive protein (42) 42
immunology (41) 41
middle aged (41) 41
tocilizumab (41) 41
inflammasome (40) 40
adolescent (39) 39
pediatrics (39) 39
safety (39) 39
care and treatment (38) 38
antirheumatic agents - therapeutic use (37) 37
medicine, general & internal (36) 36
disease (35) 35
interleukin 1 (34) 34
management (34) 34
treatment (34) 34
abridged index medicus (33) 33
child, preschool (33) 33
internal medicine (33) 33
amyloidosis (32) 32
autoinflammatory diseases (32) 32
multicenter (32) 32
therapy (32) 32
animals (31) 31
cardiac & cardiovascular systems (31) 31
muckle-wells-syndrome (30) 30
patients (30) 30
placebo-controlled trial (30) 30
cold autoinflammatory syndrome (28) 28
drug therapy (28) 28
interleukin-1 - antagonists & inhibitors (28) 28
macrophage activation syndrome (28) 28
mutation (28) 28
systemic juvenile idiopathic arthritis (28) 28
aged (27) 27
il-1 (27) 27
il-1β (27) 27
open-label (27) 27
pathogenesis (27) 27
periodic syndrome (27) 27
research (27) 27
risk factors (27) 27
anti-inflammatory agents - therapeutic use (26) 26
cryopyrin-associated periodic syndrome (26) 26
etanercept (26) 26
medicine (26) 26
patient (26) 26
receptor antagonist anakinra (26) 26
young adult (26) 26
antibodies, monoclonal - adverse effects (25) 25
colchicine - therapeutic use (25) 25
interleukin-1β (25) 25
analysis (24) 24
medicine, research & experimental (24) 24
fever (23) 23
methotrexate (23) 23
cardiovascular diseases (22) 22
genetic aspects (22) 22
health aspects (22) 22
antibodies, monoclonal - administration & dosage (21) 21
cardiovascular disease (21) 21
cryopyrin-associated periodic syndromes - drug therapy (21) 21
familial mediterranean fever - drug therapy (21) 21
gout suppressants - therapeutic use (21) 21
monoclonal antibodies (21) 21
allopurinol (20) 20
cryopyrin-associated periodic syndromes (20) 20
diagnosis (20) 20
follow-up (20) 20
interleukin-1 beta (20) 20
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (460) 460
German (16) 16
Russian (14) 14
French (8) 8
Japanese (3) 3
Polish (3) 3
Dutch (2) 2
Portuguese (1) 1
Slovenian (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature reviews. Rheumatology, 12/2018
Journal Article
Scandinavian Journal of Rheumatology, ISSN 0300-9742, 05/2019, Volume 48, Issue 3, pp. 235 - 238
Objectives: Schnitzler syndrome (SchS) is an autoinflammatory disorder characterized by chronic urticaria, fever, and monoclonal gammopathy. The success of... 
CANAKINUMAB | RHEUMATOLOGY
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 12/2018, Volume 72, Issue 25, pp. 3320 - 3331
Life-threatening cardiovascular events occur despite control of conventional risk factors. Inflammation, as measured by high-sensitivity C-reactive protein... 
atherosclerosis | canakinumab | interleukin-1 | CANTOS | inflammation
Journal Article
Annual Review of Medicine, ISSN 0066-4219, 2014, Volume 65, pp. 223 - 244
Monogenic autoinflammatory syndromes present with excessive systemic inflammation including fever, rashes, arthritis, and organ-specific inflammation and are... 
Hereditary periodic fever syndromes | Interleukin-1 | Canakinumab | Anakinra | Rilonacept | rilonacept | anakinra | hereditary periodic fever syndromes | canakinumab | interleukin-1
Journal Article
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, ISSN 0392-856X, 07/2014, Volume 32, Issue 4, pp. S171 - S171
Journal Article
Frontiers in Pharmacology, ISSN 1663-9812, 10/2016, Volume 7, p. 380
Journal Article
Blood, ISSN 0006-4971, 03/2018, Volume 131, Issue 9, pp. 974 - 981
To date, the pathogenic mechanisms underlying Schnitzler syndrome remain obscure, in particular, the interplay between the monoclonal protein and increased... 
RECEPTOR ANTAGONIST ANAKINRA | EFFICACY | SAFETY | CANAKINUMAB | PERIODIC SYNDROMES | INFLAMMASOME | DISEASE | FOLLOW-UP | HEMATOLOGY | RILONACEPT | MOSAICISM | Immunobiology and Immunotherapy
Journal Article
ANNALS OF INTERNAL MEDICINE, ISSN 0003-4819, 10/2018, Volume 169, Issue 8, pp. 535 - 535
Background: Although studies have shown that interleukin-1 beta (IL-1 beta) inhibitors can shorten gout attacks, whether they can prevent gout attacks is... 
PATHOGENESIS | MEDICINE, GENERAL & INTERNAL | MULTICENTER | CANAKINUMAB | DISEASE | RISK | NLRP3 INFLAMMASOME | PREVALENCE | HEALTH | ARTHRITIS
Journal Article
CLINICAL RHEUMATOLOGY, ISSN 0770-3198, 01/2017, Volume 36, Issue 1, pp. 191 - 197
This study aimed to evaluate the role of interleukin (IL)-1 inhibitors anakinra (ANA) and canakinumab (CAN) in the treatment of Beh double dagger et's disease... 
MANAGEMENT | EFFICACY | SAFETY | Behcet's disease | RECEPTOR | GEVOKIZUMAB | BEHCETS-DISEASE | RHEUMATOLOGY | Canakinumab | Treatment | Uveitis | LABEL | PATIENT | Anakinra
Journal Article
European Heart Journal, ISSN 0195-668X, 10/2018, Volume 39, Issue 38, pp. 3511 - 3517
Abstract Aims The CANTOS trial underscored the efficacy of selective antibody-based interleukin (IL)-1β inhibition with Canakinumab in secondary prevention of... 
Stroke | Monoclonal antibody | Canakinumab | IL-1β | Middle cerebral artery occlusion
Journal Article
Pediatrics International, ISSN 1328-8067, 11/2019, Volume 61, Issue 11, pp. 1173 - 1174
Journal Article
Clinical Rheumatology, ISSN 0770-3198, 5/2016, Volume 35, Issue 5, pp. 1281 - 1286
Growing data have provided encouraging results on the use of interleukin (IL)-1 inhibitors in Behçet’s disease (BD). This study was aimed at reporting the... 
Therapy | Medicine & Public Health | Biologics | Rheumatology | Anti-interleukin-1 | Behçet’s disease | Canakinumab | Anakinra
Journal Article
Frontiers in Pharmacology, ISSN 1663-9812, 06/2017, Volume 8, p. 369
Background: Interleukin (IL)-1 plays a crucial role in the pathogenesis of Adult onset Still's disease (AOSD). Objectives: To evaluate the efficacy and safety... 
Adult-onset Still's disease | Treatment | Canakinumab | Anakinra | Interleukin (IL)-1 | treatment | DIAGNOSIS | PROFILES | EFFICACY | JUVENILE IDIOPATHIC ARTHRITIS | CYTOKINE | interleukin (IL)-1 | SEPSIS | anakinra | RESISTANT | canakinumab | PHARMACOLOGY & PHARMACY | MANIFESTATIONS
Journal Article
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, ISSN 0392-856X, 07/2014, Volume 32, Issue 4, pp. S172 - S172
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2017, Volume 377, Issue 12, pp. 1119 - 1131
Patients with myocardial infarction and a high-sensitivity CRP level of 2 mg or more per liter were assigned to one of three canakinumab doses or placebo. The... 
C-REACTIVE PROTEIN | MEDICINE, GENERAL & INTERNAL | HEART-DISEASE | MYOCARDIAL-INFARCTION | STATIN THERAPY | CLONAL HEMATOPOIESIS | INFLAMMATION | CARDIOVASCULAR-DISEASE | INTERLEUKIN-1-BETA INHIBITION | RISK | CORONARY-ARTERY-DISEASE | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Male | Secondary Prevention | Infection - etiology | Incidence | Dose-Response Relationship, Drug | Anti-Inflammatory Agents - adverse effects | C-Reactive Protein - metabolism | Lipids - blood | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Anti-Inflammatory Agents - administration & dosage | Female | Neutropenia - chemically induced | Interleukin-1beta - antagonists & inhibitors | Stroke - prevention & control | Atherosclerosis - drug therapy | Double-Blind Method | Interleukin-1beta - immunology | Atherosclerosis - blood | Myocardial Infarction - drug therapy | Antibodies, Monoclonal - administration & dosage | Aged | Myocardial Infarction - prevention & control | Myocardial infarction | Cerebral infarction | Stroke | Heart attacks | C-reactive protein | Cytokines | Clinical trials | Cardiovascular disease | Innate immunity | Inflammation | Angina | Angina pectoris | Thrombosis | Cholesterol | Disease prevention | Proteins | Arteriosclerosis | Atherosclerosis | Cardiovascular diseases | Health risk assessment | Drug therapy | Drug dosages | Klinisk medicin | Clinical Medicine
Journal Article